

54. (New) Use according to claim 11, wherein the composition does not stimulate cancer cells that are estrogen receptor-positive.

55. (New) Use according to claim 12, wherein the lack of interaction is lack of stimulation of breast cancer cells.

56. (New) Use according to claim 13, wherein the lack of interaction is lack of stimulation of breast cancer cells.

57. (New) A method according to claim 28, wherein the composition is free from a stimulating effect on breast cancer.

58. (New) A method according to claim 39, wherein the composition has substantially no agonizing and substantially no antagonizing effect on the effect of estradiol on breast cancer cells.

REMARKS

I. CLAIM AMENDMENTS AND NEW CLAIMS

Applicants amended some claims to place them in a format customary in U.S. practice. Applicants also added new claims 51-58, which are supported by the application, considered as a whole, such as PCT claims 1, 9, 10-13, 28 and 39, submitted during the international stage on October 1, 2001.

II. REQUEST FOR ALLOWANCE

Applicants submit that all claims in the application are in condition for allowance, an indication of which is solicited.

In the event any fees are incurred upon the filing of these documents, please charge the undersigned's Deposit Account No. 50-0206.


Respectfully submitted,

HUNTON & WILLIAMS

Date:

January 15, 2002

By:



Stanislaus Aksman

Registration No. 28,562

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Ph. (202) 955-1500
Fax (202) 778-2201

202050" T 460E00T